WO2022269027 - ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS
National phase entry:
Publication Number
WO/2022/269027
Publication Date
29.12.2022
International Application No.
PCT/EP2022/067318
International Filing Date
24.06.2022
Title **
[English]
ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS
[French]
ANTAGONISTES DE CXCR4 À BASE D'ISOQUINOLÉINE ET DE PYRIDINE
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
DEHAEN, Wim
DE JONGHE, Steven
SCHOLS, Dominique
VAN LOY, Tom
Priority Data
21181444.7
24.06.2021
EP
21204648.6
26.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2082 | |
| EPO | Filing, Examination, Granting | 8490 | |
| Japan | Filing, Examination, Granting | 2155 | |
| South Korea | Filing, Examination, Granting | 2065 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,532
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to isoquinoline and pyridine based CXCR4 antagonists and their use in the treatment and prevention of viral infections such as HIV.[French]
L'invention concerne des antagonistes CXCR4 à base d'isoquinoléine et de pyridine et leur utilisation dans le traitement et la prévention d'infections virales telles que le VIH.